CHARLOTTESVILLE — A new vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing, according to scientists at University of Virginia Medical Center and Virginia Polytechnic University.
Vaccines created by UVA Health’s Dr. Steven L. Zeichner and Virginia Tech’s Dr. Xiang-Jin Meng prevented pigs from being becoming ill with a pig model coronavirus, porcine epidemic diarrhea virus (PEDV). The vaccine was developed using an innovative approach that Zeichner says might one day open the door to a universal vaccine for coronaviruses, including coronaviruses that previously threatened pandemics or perhaps even coronaviruses that cause some cases of the common cold.
Their coronavirus vaccine offers several advantages that could overcome major obstacles to global vaccination efforts. It would be easy to store and transport, even in remote areas of the world, and could be produced in mass quantities using existing vaccine-manufacturing factories.
The UVA and Virginia Tech scientists created the vaccine using a new platform Zeichner invented to rapidly develop new vaccines. So the testing success bodes well for both the COVID-19 vaccine and Zeichner’s vaccine-development approach.
“Our new platform offers a new route to rapidly produce vaccines at very low cost that can be manufactured in existing facilities around the world, which should be particularly helpful for pandemic response,” said Zeichner.
New vaccine approach
Zeichner’s new vaccine-production platform involves synthesizing DNA that directs the production of a piece of the virus that can instruct the immune system how to mount a protective response.
That DNA is inserted into another small circle of DNA called a plasmid that can reproduce within bacteria. The plasmid is then introduced to the common E. coli bacteria, instructing the bacteria to place pieces of proteins on their surfaces.
One major innovation is that E. coli has had a large number of its genes deleted. Removing many of the bacteria’s genes, including those that make up part of its exterior surface or outer membrane, appears to substantially increase the ability of the immune system to recognize and respond to the vaccine antigen placed on the surface of the bacteria.
“Killed whole-cell vaccines are currently in widespread use to protect against deadly diseases like cholera and pertussis,” said Zeichner. “Factories in many low-to-middle-income countries around the world are making hundreds of millions of doses of those vaccines per year now, for a $1 per dose or less. It may be possible to adapt those factories to make this new vaccine. Since the technology is very similar, the cost should be similar too.”
The entire process, from identifying a potential vaccine target to producing the gene-deleted bacteria that have the vaccine antigens on their surfaces, can take place quickly, in only two to three weeks, making the platform ideal for responding to a pandemic.
More:Augusta County Sheriff’s Office investigates gold scam
Targeting coronavirus
Zeichner and Meng’s vaccine takes an unusual approach because it targets a part of the spike protein of the virus, the “viral fusion peptide,” that is essentially universal among coronaviruses. The fusion peptide has not been observed to differ at all in the many genetic sequences of SARS-CoV-2, the virus that causes COVID-19.
Meng and Zeichner made two vaccines, one designed to protect against COVID-19, and another designed to protect against porcine epidemic diarrhea virus. PEDV and the virus that causes COVID-19 are both coronaviruses, but they are distant relatives. Like all coronaviruses, they share several of the amino acids that constitute the fusion peptide. PEDV infects pigs, causing diarrhea, vomiting and high fever, and has been a large burden on pig farmers around the world. When PEDV first appeared in pig herds in the US, it killed almost 10% of U.S. pigs — a pig pandemic.
One advantage of studying PEDV in pigs is that Meng and Zeichner could study the ability of the vaccines to offer protection against a coronavirus infection in its native host — in this case, pigs. The other models that have been used to test COVID-19 vaccines study SARS-CoV-2 in non-native hosts, such as monkeys or hamsters, or in mice that have been genetically engineered to enable them to be infected with SARS-CoV-2. Pigs are also similar in physiology and immunology to people — they may be the closest animal models to people other than primates.
In some unexpected results, Meng and Zeichner observed that both the vaccine against PEDV and the vaccine against SARS-CoV-2 protected the pigs against illness caused by PEDV. The vaccines did not prevent infection, but they protected the pigs from developing severe symptoms, much like the observations made when primates were tested with candidate COVID-19 vaccines.
The vaccines also primed the immune system of the pigs to mount a much more vigorous immune response to the infection. If both the PEDV and the COVID-19 vaccines protected the pigs against disease caused by PEDV and primed the immune system to fight the disease, it is reasonable to think that the COVID-19 vaccine would also protect people against severe COVID-19 disease, the scientists say.
More:Chase videos capture driver’s reaction, assistance in catching Staunton fugitive on I-64
Next steps
Additional testing — including human trials — would be required before the new COVID-19 vaccine could be approved by the federal Food and Drug Administration or other regulatory agencies around the world for use in people, but the collaborators are pleased by the early successes of the vaccine-development platform.
“We’re trying to make the best candidate vaccine that we can,” said Zeichner. “Once we get that and once we test that in animal models then we will be in a position to move on in animal trials.”
Realistically, this could happen within a year, possibly months, he said. “If we could get something into humans within a year that would be great.”
The researchers have published their findings in the Proceedings of the National Academy of Sciences of the United States of America scientific journal. The findings are under peer review.
Monique Calello (she/her) is The News Leader’s health reporter. You can reach her at mcalello@newsleader.com and follow on Twitter @moniquecalello.